Transcenta is a clinical stage biopharmaceutical company that fully integrates antibody-based biotherapeutics discovery, research, development and manufacturing. On September 29, 2021, Transcenta was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 06628. Transcenta has established global footprint, with Headquarters and Discovery, Clinical and Translational Research Center in Suzhou, Process and Product Development Center and Manufacturing Facility in Hangzhou, and Clinical Development Centers in Beijing, Shanghai and Guangzhou in China and in Princeton, US, and External Partnering Center in Boston and Los Angeles, US. Transcenta is developing nine therapeutic antibody molecules for oncology and selected non-oncology indications including bone and kidney disorders. For more information, please visit www.transcenta.com.
Looking for a particular Transcenta employee's phone or email?
Transcenta Questions
The Transcenta annual revenue was $28.2 million in 2026.
Xueming Qian is the Founder, Chairman and CEO of Transcenta.
57 people are employed at Transcenta.
Transcenta is based in Princeton, New Jersey.
The NAICS codes for Transcenta are [541, 5417, 54, 54171, 541714].
The SIC codes for Transcenta are [87, 873].
Top Transcenta Employees
-
Xueming Qian
Founder, Chairman and CEO at Transcenta
Princeton, NJ, US25+ -
Christopher Hwang
Chief Technology Officer at Transcenta
Newton, MA, US35+ -
22
-
Gigi Lam
SVP - US Business Operations at Transcenta
New York, NY, US35+ -
Xichen Zhang
SVP Manufacturing at Transcenta
Thousand Oaks, CA, US25+ -
12
-
11
Related Companies
